Results from a just-published landmark trial could lead to the first-ever approved drug for the treatment of systemic scleroderma-associated interstitial lung disease.
An inside look into the ILD Clinic of a large, tertiary referral center.
Cleveland Clinic’s Rheumatic Lung Disease Program is currently engaged in three major multicenter trials whose common aim is to improve outcomes for patients with rheumatic disease and pulmonary hypertension or interstitial lung disease.
The SENSCIS® study, co-led by Cleveland Clinic’s Kristin Highland, MD, explores the use of nintedanib in patients with scleroderma-associated interstitial lung disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Approved vasodilation therapies generally don’t improve function in patients with pulmonary hypertension associated with connective tissue disease. The Catalyst study explores the use of bardoxolone in these patients.
The TRAIL-1 study explores the use of pirfenidone, an antifibrotic agent approved for idiopathic pulmonary fibrosis, in patients with rheumatoid arthritis-associated interstitial lung disease.
IPF is still underappreciated by pulmonologists and primary care physicians. This article attempts to close that information gap by offering an overview of available treatment modalities.
Our multidisciplinary team treats local and national patients with this chronic and progressive lung disease.
Several aspects of this case deviate from the classic SLE presentation, but uncommon cases are common in Cleveland Clinic’s Lupus Clinic.
In this unusual case, a referring pathologist suspects adenocarcinoma; Dr. Mukhopadhyay explains why another diagnosis is a better fit.